Bausch Health Companies (NYSE:BHC) Trading Down 5.2% – What’s Next?

Shares of Bausch Health Companies Inc. (NYSE:BHC) dropped 5.2% on Monday . The stock traded as low as $7.01 and last traded at $7.05. Approximately 488,195 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 3,154,331 shares. The stock had previously closed at $7.43.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BHC. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Royal Bank of Canada reduced their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Thursday, January 30th. Finally, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Bausch Health Companies presently has a consensus rating of “Hold” and a consensus price target of $7.58.

Bausch Health Companies Stock Performance

The stock has a fifty day simple moving average of $7.74 and a two-hundred day simple moving average of $7.46. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -15.30 and a beta of 0.68.

Institutional Trading of Bausch Health Companies

Several institutional investors have recently made changes to their positions in the company. Handelsbanken Fonder AB grew its stake in shares of Bausch Health Companies by 18.4% during the 4th quarter. Handelsbanken Fonder AB now owns 65,100 shares of the company’s stock worth $525,000 after acquiring an additional 10,100 shares during the period. Principal Securities Inc. grew its stake in Bausch Health Companies by 39.7% in the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock worth $155,000 after buying an additional 5,464 shares in the last quarter. Tobam increased its stake in Bausch Health Companies by 10.4% in the fourth quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after acquiring an additional 1,422 shares during the last quarter. DGS Capital Management LLC purchased a new stake in Bausch Health Companies during the fourth quarter valued at about $143,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after acquiring an additional 1,263,706 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.